Author(s): Ujwala Wasnik, Sameer Lakade, Minal Harde, Mugdha Banduke, Trupti Dighe, Abhijeet More, Prathmsh Nale, Ajay Patange, Shivshankar Waghmare, Dnyneshwar Kharsade

Email(s): minalresearch@gmail.com

DOI: 10.52711/0974-360X.2023.00690   

Address: Ujwala Wasnik1, Sameer Lakade2, Minal Harde3*, Mugdha Banduke3, Trupti Dighe3,
Abhijeet More3, Prathmsh Nale3, Ajay Patange3, Shivshankar Waghmare3, Dnyneshwar Kharsade3
1Taywade College of Pharmacy, Koradi, Nagpur, Maharashtra, India.
2RMD Institute of Pharmaceutical Education & Research, Pune, Maharashtra, India.
3PES’s Modern College of Pharmacy, Sector No. 21, Yamuna Nagar, Nigdi, Pune, Maharashtra, India.
*Corresponding Author

Published In:   Volume - 16,      Issue - 9,     Year - 2023


ABSTRACT:
Background: This paper describes the development of HPTLC method for the quantitative determination of Ruxolitinib in bulk and tablet dosage form using a systemic approach. A. simple, precise, accurate and specific high performance thin layer chromatographic method has been developed and validated for the Ruxolitinib in bulk and marketed formulation. Methods: The solvent system was 8.0:2.0:0.05 v/v/v of chloroform, methanol, and formic acid. This system was found to give compact spots for Ruxolitinib (Rf value of (0.71±0.02) Densitometric analysis of Ruxolitinib was tested in the absorbance mode at 236nm. Results: The developed method produced linear results with R2 = 0.998 for a range of 100 - 600ng/band. The accuracy of the method was determined at 80, 100, and 120% level. The % recoveries were found to be 100.01%, 99.13%, and 99.82% which are within the limit of 99% to 101%. The LOD and LOQ were found to be 8.19 ng/band and 25.06ng/band indicating the sensitivity of the method. Using the developed method, it was found that intraday and interday RSD values were less than 2%. The method was also found to be robust as indicated by the % RSD values less than 2%. Conclusion: The present method was validated according to the ICH guidelines and it is applied successfully for the determination of Ruxolitinib in tablets.


Cite this article:
Ujwala Wasnik, Sameer Lakade, Minal Harde, Mugdha Banduke, Trupti Dighe, Abhijeet More, Prathmsh Nale, Ajay Patange, Shivshankar Waghmare, Dnyneshwar Kharsade. Green HPTLC - Densitometric approach for quantitation of Ruxolitinib in bulk and marketed formulation. Research Journal of Pharmacy and Technology 2023; 16(9):4219-4. doi: 10.52711/0974-360X.2023.00690

Cite(Electronic):
Ujwala Wasnik, Sameer Lakade, Minal Harde, Mugdha Banduke, Trupti Dighe, Abhijeet More, Prathmsh Nale, Ajay Patange, Shivshankar Waghmare, Dnyneshwar Kharsade. Green HPTLC - Densitometric approach for quantitation of Ruxolitinib in bulk and marketed formulation. Research Journal of Pharmacy and Technology 2023; 16(9):4219-4. doi: 10.52711/0974-360X.2023.00690   Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-9-34


REFERENCES:
1.    https://pubchem.ncbi.nlm.nih.gov/compound/Ruxolitinib
2.    https://en.wikipedia.org/wiki/Ruxolitinib
3.    LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Ruxolitinib. [Updated 2021 May 11]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548534/
4.    Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis. J Dermatolog Treat. 2020; 31:33–40. https:// doi.org/10.1080/09546634.2019.1577549.
5.    Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019; 10: 2847. https://doi.org/10.3389/fmmu.2019.02847.
6.    Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase fam ily in autoimmune skin diseases. Front Immunol. 2019; 10: 2342. https://doi.org/10.3389/fmmu.2019.02342.
7.    Welsch K, Holstein J, Laurence A, Ghoreschi K. Targeting JAK/ STAT signalling in infammatory skin diseases with small mol ecule inhibitors. Eur J Immunol. 2017; 47: 1096–107. https://doi. org/10.1002/eji.201646680.
8.    Rerknimitr P, Otsuka A, Nakashima C, Kabashima K. The eti opathogenesis of atopic dermatitis: barrier disruption, immuno logical derangement, and pruritus. Infamm Regen. 2017; 37: 14. https://doi.org/10.1186/s41232-017-0044-7.
9.    Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017; 139: S65-s76. https://doi.org/10.1016/j.jaci.2017.01.011.
10.    Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yanco poulos GD. Targeting key proximal drivers of type 2 infammation in disease. Nat Rev Drug Discov. 2016; 15: 35–50. https://doi.org/ 10.1038/nrd4624.
11.    Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic infammatory skin disease atopic dermatitis. Jakstat. 2013; 2: e24137. https://doi.org/10.4161/jkst. 24137. 566 X. Gong et al.
12.    Hashimoto T, Sakai K, Sanders KM, Yosipovitch G, Akiyama T. Antipruritic efects of Janus kinase inhibitor tofacitinib in a mouse model of psoriasis. Acta Derm Venereol. 2019; 99: 298– 303. https://doi.org/10.2340/00015555-3086.
13.    Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015; 73: 395–9. https://doi.org/10.1016/j. jaad.2015.06.045.
14.    Nakagawa H, Nemoto O, Yamada H, Nagata T, Ninomiya N. Phase 1 studies to assess the safety, tolerability and pharmacoki netics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis. J Dermatol. 2018; 45: 701–9. https://doi.org/10.1111/1346-8138. 14322.
15.    Nakagawa H, Nemoto O, Igarashi A, Nagata T. Efcacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol. 2018;178:424–32. https://doi.org/10.1111/bjd.16014.
16.    Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175:902–11. https://doi. org/10.1111/bjd.14871.
17.    Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/ JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020;145:572–82. https://doi.org/10.1016/j.jaci.2019.08.042.
18.    Kim BS, Sun K, Papp K, Venturanza M, Nasir A, Kuligowski ME. Efects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-rang ing, vehicle- and active-controlled study. J Am Acad Dermatol. 2020;82:1305–13. https://doi.org/10.1016/j.jaad.2020.02.009.
19.    Incyte Corporation. JAKAFI ruxolitinib tablets—highlights of prescribing information Incyte Corporation, Wilmington, DE, USA. 2020. https://www.jakaf.com/pdf/prescribing-information. pdf. Accessed 19 May 2020.
20.    Charlier B. Marino L. Dal Piaz F. et al. Development and Validation of a Reverse-Phase High-Performance Liquid Chromatography with Fluorescence Detection (RP-HPLC-FL) Method to Quantify Ruxolitinib in Plasma Samples. Anal Lett. 2019;52(8):1328-1339. doi:10.1080/00032719.2018.1537283
21.    Merienne C. Rousset M. Ducint D. et al. High throughput routine determination of 17 tyrosine kinase inhibitors by LC–MS/MS. J Pharm Biomed Anal. 2018;150:112-120. doi:10.1016/j.jpba.2017.11.060
22.    Rood JJM. Schellens JHM. Beijnen JH. Sparidans RW. Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology. J Pharm Biomed Anal. 2016;130:244-263. doi:10.1016/j.jpba.2016.06.037
23.    Koller D. Vaitsekhovich V. Mba C. et al. Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring. Talanta. 2020;208(August):120450. doi:10.1016/j.talanta.2019.120450
24.    Mrs. Aishwarya P. Joglekar. Method Development and Validation for the Estimation of Telmisartan and Chlorthalidone in Bulk and Pharmaceutical Dosage form by HPTLC Method. Research J. Pharm. and Tech. 8(4): April, 2015; Page 376-381. doi: 10.5958/0974-360X.2015.00063.3
25.    Kaur, I, Wakode, S, & Singh, H. P. (2016). Development and validation of a stability-indicating high performance thin layer chromatography (HPTLC) method for estimation of canagliflozin in bulk and pharmaceutical dosage form. Journal of Applied Pharmaceutical Science, 6(5), 51-57
26.    Biswal S. Mondal S. Mondal P. A New Stability Indicating High Performance Liquid Chromatography Method for the Estimation of Ruxolitinib in Bulk and Tablet Dosage Form. Pharm Methods. 2019;10(2):53-57. doi:10.5530/phm.2019.2.10
27.    Häkkinen MR. Heinosalo T. Saarinen N. et al. Analysis by LC–MS/MS of endogenous steroids from human serum. plasma. endometrium and endometriotic tissue. J Pharm Biomed Anal. 2018;152:165-172. doi:10.1016/j.jpba.2018.01.034
28.    Veeraraghavan S. Thappali S. Viswanadha S. et al. Simultaneous quantification of Ruxolitinib and nilotinib in rat plasma by LC-MS/MS: Application to a pharmacokinetic study. J Pharm Biomed Anal. 2014;94:125-131. doi:10.1016/j.jpba.2014.01.040
29.    ICH: Q2 (R1), 2005. Validation of analytical procedures: text and methodology. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf
30.    Prajakta H Patil, B. M. Gurupadayya, P. D. Hamrapurkar. Stability Indicating HPTLC Determination of Tadalafil Hydrochloride in Bulk Drug and Pharmaceutical Formulations. Research J. Pharm. and Tech 2020; 13(6):2608-2614. doi: 10.5958/0974-360X.2020.00464.3
31.    KB Premakumari, AR Mahesh, V Murugan, V Ezhilarasan. Simultaneous Estimation of Paracetamol and Zaltoprofen in Pharmaceutical Dosage Form by HPTLC. Research J. Pharm. and Tech. 2019; 12(5):2075-2078. doi: 10.5958/0974-360X.2019.00343.3
32.    Lata Kothapalli, Harshali Lunkad, Asha Thomas, Rahul Tupe. Design of Experiment Based Validated HPTLC Method for Analysis of Deflazacort in Tablet Formulation. Research J. Pharm. and Tech 2020; 13(5):2366-2372. doi: 10.5958/0974-360X.2020.00425.4
33.    N. Tamilselvi, R. Arivukkarasu, Sasikala R, Shahanas, Shamina, Sreelakshmi Jayan. Development and Validation of HPTLC method for the Determination of Efavirenz in Tablet Dosage Form. Research J. Pharm. and Tech. 2018; 11(3): 885-888. doi: 10.5958/0974-360X.2018.00169.5
34.    S. J. Daharwal, Suman Shrivastava. Preliminary Phytochemical Screening and HPTLC Fingerprinting of Extracts of Thuja occidentalis. Research J. Pharm. and Tech. 2019; 12(10):4782-4784. doi: 10.5958/0974-360X.2019.00825.4
35.    Ajay Kumar Meena, P. Rekha, V. Poorna, V. Jayarega, K. N. Swathi, R. Ilavarasan. Standardisation and HPTLC finger print profile of poly herbal churna, An Ayurvedic Formulation. Research J. Pharm. and Tech 2020; 13(3):1361-1367. doi: 10.5958/0974-360X.2020.00251.6
36.    GG Tapadiya, UA Deokate, MV Metku, SS Saboo, SS Khadabadi. Quantitative Estimation of Sennoside B from Capsule Dosage Form by HPTLC. Research J. Pharm. and Tech. 2(1): Jan.-Mar. 2009; Page 97-100
37.    Sattwik Das, Shailendra Lariya, Sunil Mistry. Chromatographic Finger Print analysis of Dryopteris cochleata by HPTLC technique. Research J. Pharm. and Tech. 8(10): Oct., 2015; Page 1394-1398. doi: 10.5958/0974-360X.2015.00250.4
38.    Shubhangi V. Sutar, Veerendra C. Yeligar. Degradation Kinetic Study of Melatonin in Alkaline and Acidic Medium by Validated Stability Indicating HPTLC Method. Research J. Pharm. and Tech 2020; 13(2):523-528. doi: 10.5958/0974-360X.2020.00099.2
39.    V. Jayashree, Malarkodi Velraj. HPTLC Fingerprinting Profile and GC-MS Analysis of Aqueous extract of Alstonia scholaris Linn. Bark. Research J. Pharm. and Tech. 2019; 12(12): 5706-5710. doi: 10.5958/0974-360X.2019.00987.9

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available